Lung Cancer Trial Expanded Diversity and Age Criteria
The ongoing COPERNICUS trial aims to make study data more representative for patients with EGFR-mutated lung cancer.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Do you trust that new, less-invasive cancer treatment regimens will improve patient health outcomes?
The COPERNICUS trial is currently evaluating a combination of subcutaneous amivantamab and lazertinib for patients with EGFR-mutated advanced non-small cell lung cancer. Published as of October 13, 2026, the study design prioritizes broader enrollment regarding age and greater racial and ethnic diversity.
Why it matters
By allowing patients to undergo one cycle of chemotherapy while waiting for next-generation sequencing results, the trial design improves access for those needing immediate intervention. This approach aims to reflect a more inclusive, real-world population while establishing this regimen as a potential standard treatment.
The COPERNICUS trial is an ongoing study evaluating the efficacy of subcutaneous amivantamab plus lazertinib in patients with advanced non-small cell lung cancer. The study is specifically designed to assess outcomes across a more diverse age, racial, and ethnic demographic.
The players
Starling Oncology
A clinical practice setting involved in the evaluation of oncology treatment protocols.
Tennessee Oncology
A clinical practice setting participating in the administration of cancer research and care.
The details
The treatment protocol utilizes subcutaneous amivantamab and lazertinib to target EGFR mutations. To ensure patient safety during administration, the regimen requires a single day of steroid use. Additionally, patients are prescribed prophylactic anticoagulation therapy to mitigate the risk of venous thromboembolism.
Timeline
October 13, 2026: The analysis of the trial protocols was published.
Health Landscape
The COPERNICUS trial shifts standard lung cancer enrollment models by prioritizing demographic diversity in its research protocol. This study represents an evolution in clinical trial architecture by explicitly designing for broader patient representation compared to traditional, more restrictive criteria.
For patients navigating advanced non-small cell lung cancer, this trial highlights the importance of timely genetic testing through next-generation sequencing. You should discuss with your oncologist whether clinical trial enrollment options offer a suitable path for your specific diagnosis.
The takeaway
The COPERNICUS trial is working to address historical gaps in patient representation for advanced lung cancer treatments. Patients should consult their care team about whether genetic sequencing and clinical trial participation are appropriate for their treatment plan.
Further reading
For more on the current landscape of thoracic oncology research, visit Cancer.
Live Poll
Do you trust that new, less-invasive cancer treatment regimens will improve patient health outcomes?
